The onset of Covid-19 in India was always going to stretch the country’s healthcare infrastructure to the limit. What many didn’t see coming, though, was that it would turn the hospital business on its head altogether.

Within the first few months of the pandemic, the sector’s cash cows—large hospitals in India’s major cities—began to dry up. In better days, their secret sauce was simple. They attracted patients from other countries as well as from smaller cities and towns because of their superior technology, talent, and expertise in conducting advanced surgeries.

India’s first wave of Covid-19—from March 2020 to September 2020—put an end to that. International travel was halted, and even those within the country were wary of travelling to big cities, where the virus was more rampant. Elective surgeries were put on hold. While Covid patients occupied a large share of the beds available at these hospitals, the price of treatment was often capped by state governments.

Revenue plummeted, and with it, so did profits.

Bengaluru-headquartered Narayana Health—one of the five largest hospital chains in the country—experienced this first-hand. The hospital chain has 23 hospitals and heart centres, eight of which are situated in the country’s metros. Despite accounting for just over a third of the chain’s locations, they contribute over 80% of its revenue. Their EBITDA margins EBITDA margins EBITDA margin The EBITDA margin is a measure of a company's operating profit as a percentage of its revenue. The acronym EBITDA stands for earnings before interest, taxes, depreciation, and amortisation go as high as 25%, says Viren Shetty, the chain’s chief operating officer. Covid hobbled them, adversely affecting Narayana Health’s revenue and earnings in 2020, says Shetty.

There was a silver lining, though. The Ken spoke to senior executives at six hospital chains, doctor-entrepreneurs, and investors across the country. All of them agreed that while flagship hospitals suffered for the first 4-5 months of Covid’s onset, hospitals in smaller cities did not. These units have traditionally struggled to attract patients, medical talent, or investors at scale. When big hospitals were still reeling from the new, Covid-induced reality, however, these small hospitals bounced back quickly.

Patients who could no longer travel to major cities made do with local options. With Covid’s first wave being largely restricted to India’s metros as well, business went on as usual. According to Narayana Health’s Shetty, the chain’s 150-bed hospital Shimoga, Karnataka, saw earnings and revenue recover to pre-Covid levels as there were limited Covid cases in the city. 

Manipal Hospitals—the country’s second-largest hospital chain—saw a similar phenomenon at its non-metro hospitals, such as those in Udupi, Patiala, and Vijayawada. According to Dilip Jose, managing director and CEO of Manipal Hospitals, some small hospitals in West Bengal actually saw their revenues grow, as patients who would normally travel to South India for treatment used neighbouring healthcare facilities instead.

AUTHOR

Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.